Glucagon-like peptide 1 (GLP-1) receptor agonists offer promise in weight and cardiovascular risk reduction, but their use must complement—not replace—lifestyle interventions within a holistic, patient-centered care model.
Navaira Shoaib, MBBS
Advertisement
Articles by Navaira Shoaib, MBBS
Advertisement
Latest Updated Articles
GLP-1 Receptor Agonists: Trend, Necessity, or Blessing?December 8th 2025
Advertisement
Advertisement
Trending on AJMC
1
NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues
2
Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?
3
Provider Trust, Social Media Use Can Shape Vaccine Myth Belief
4
MS Likely Unfolds Along a Continuum Years Before First Symptoms
5